N-Acetyl Cysteine (NAC) per Inflammatory Bowel Disease (IBD) — General
D Ricerca Esiste solo ricerca preliminare (studi di laboratorio, segnalazioni di casi).Pilot data only. Glutathione precursor may reduce oxidative stress in IBD. Requires larger clinical trials.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dn\u002Dacetyl\u002Dcysteine\u0026condition\u003Dinflammatory\u002Dbowel\u002Ddisease';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
In sintesi
Pilot data only. Glutathione precursor may reduce oxidative stress in IBD. Requires larger clinical trials.
Key Study Findings
Review
Nanocatalytic Antioxidation: A General Chemical Approach for Alleviating Oxidative Stress in Diseases.
Dose: None
vs: None
Outcome: None
Effetto: None
None
Popolazione: Review of nanocatalytic antioxidation in diseases
Randomized Controlled Trial
16 weeks
Open-label
Exploring the role of oxidative stress and the effect of N-acetylcysteine in thiopurine-induced liver injury …
Dose: N-acetylcysteine with thiopurine
vs: Thiopurine alone (crossover)
Outcome: Liver injury markers and oxidative stress
Effetto: None
None
Popolazione: IBD patients with thiopurine-induced liver injury
Review
The emerging role of oxidative stress in inflammatory bowel disease.
Dose: None
vs: None
Outcome: Oxidative stress role in IBD pathophysiology
Effetto: None
None
Popolazione: IBD patients (Crohn's and UC)
In Vitro
4.3 weeks
Extraintestinal Manifestations in Induced Colitis: Controversial Effects of N-Acetylcysteine on Colon, Liver, and Kidney.
Dose: 150 mg/kg
vs: None
Outcome: inflammation markers
Effetto: None
None
Popolazione: Mice
Systematic Review
52 weeks
Vitamin D for the treatment of inflammatory bowel disease.
Dose: 400 IU/day
vs: placebo
Outcome: IBD disease activity
Effetto: None
None
Popolazione: Patients with IBD
Review
Role of ferroptosis in the pathogenesis and as a therapeutic target of inflammatory bowel disease …
Dose: None
vs: None
Outcome: Ferroptosis role in IBD pathogenesis
Effetto: None
None
Popolazione: IBD patients (mechanistic review)
Key Statistics
1
Studi
30
Partecipanti
↑
Positive
D
Grado
Referenced Papers
Accounts of chemical …
2025
2 citazioni
Frontiers in endocrinology
2024
165 citazioni
Basic & clinical …
2024
International journal of …
2023
59 citazioni
Pharmaceuticals (Basel, Switzerland)
2023
18 citazioni
Oxidative medicine and …
2023
11 citazioni
Vitamin D for the treatment of inflammatory bowel disease.
Systematic Review
The Cochrane database …
2023
1 citazioni
Journal of nanobiotechnology
2022
206 citazioni
International immunopharmacology
2022
21 citazioni
Journal of biochemical …
2022
5 citazioni
Medwave
2022
4 citazioni
European journal of …
2021
40 citazioni
Journal of inflammation …
2021
34 citazioni
Journal of Crohn's …
2018
91 citazioni
Redox biology
2017
34 citazioni
Digestion
2016
522 citazioni
Chemical research in …
2015
13 citazioni
Scandinavian journal of …
2013
65 citazioni
The British journal …
2012
145 citazioni
World journal of …
2012
113 citazioni
Pharmaceutical biology
2010
16 citazioni
Digestive diseases and …
2009
49 citazioni
Molecular and cellular …
2007
95 citazioni
Journal of agricultural …
2007
44 citazioni
The Tohoku journal …
2005
114 citazioni
The Journal of …
2005
63 citazioni
Journal of leukocyte …
2002
Laboratory investigation; a …
2000
116 citazioni
Role of free radicals and poly(ADP-ribose) synthetase in intestinal tight junction permeability.
Other
Molecular medicine (Cambridge, …
2000
Alimentary pharmacology & …
1999
57 citazioni
Gut
1996
297 citazioni
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosaggi di uso comune
- general:
- 600-1,200 mg/day in divided doses
- hpyloriadjunct:
- 600 mg twice daily alongside standard triple therapy
- antioxidantsupport:
- 600-900 mg/day
Limite massimo: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings
Dosaggi studiati nella ricerca
| Dosaggio | Durata | Effetto | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| N-acetylcysteine with thiopurine | 16 weeks | Positive | -- |
| None | -- | Positive | -- |
| 150 mg/kg | 4.3 weeks | Positive | -- |
| 400 IU/day | 52 weeks | Mixed | -- |
| None | -- | Neutral | -- |
| Various antioxidant compounds | -- | Positive | -- |
| None | -- | Mixed | -- |
Momento migliore per l'assunzione: With or without food; divide doses throughout the day
Safety & Side Effects
Effetti collaterali segnalati
- ⚠ Nausea and vomiting (most common, especially at higher doses)
- ⚠ Diarrhea
- ⚠ Unpleasant sulfur taste/odor
- ⚠ Headache
Interazioni note
- ● Nitroglycerin (NAC may enhance vasodilatory effects; risk of hypotension)
- ● Activated charcoal (may reduce NAC absorption)
- ● Anticoagulants (NAC may have mild antiplatelet effects)
- ● ACE inhibitors (additive hypotensive effect with nitroglycerin combination)
Livello di assunzione massimo tollerabile: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings
Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.
Frequently Asked Questions
Does N-Acetyl Cysteine (NAC) help with Inflammatory Bowel Disease (IBD) — General?
Based on 1 studies with 30 participants, there is preliminary evidence that needs more research that N-Acetyl Cysteine (NAC) may support Inflammatory Bowel Disease (IBD) — General management. Our evidence grade is D (Very Early Research).
How much N-Acetyl Cysteine (NAC) should I take for Inflammatory Bowel Disease (IBD) — General?
Studies have used various dosages. A commonly studied range is 600-1,200 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of N-Acetyl Cysteine (NAC)?
Reported side effects may include Nausea and vomiting (most common, especially at higher doses), Diarrhea, Unpleasant sulfur taste/odor, Headache. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for N-Acetyl Cysteine (NAC) and Inflammatory Bowel Disease (IBD) — General?
We rate the evidence as Grade D (Very Early Research). This rating is based on 1 peer-reviewed studies with 30 total participants. The overall direction of effect is positive.
Related Evidence
Altri ingredienti per Inflammatory Bowel Disease (IBD) — General
N-Acetyl Cysteine (NAC) per altre condizioni
References
- [1] Bowen Yang et al.. Acc Chem Res. 2025. Nanocatalytic Antioxidation: A General Chemical Approach for Alleviating Oxidative Stress in Diseases. doi:10.1021/acs.accounts.5c00408 PubMed
- [2] Peter Muro et al.. Front Endocrinol (Lausanne). 2024. The emerging role of oxidative stress in inflammatory bowel disease. doi:10.3389/fendo.2024.1390351 PubMed
- [3] Dirk P van Asseldonk et al.. Basic Clin Pharmacol Toxicol. 2024. Exploring the role of oxidative stress and the effect of N-acetylcysteine in thiopurine-induced liver injury in inflammatory bowel disease: A … doi:10.1111/bcpt.13978 PubMed
- [4] Dickson Kofi Wiredu Ocansey et al.. Int J Mol Med. 2023. Role of ferroptosis in the pathogenesis and as a therapeutic target of inflammatory bowel disease (Review). doi:10.3892/ijmm.2023.5256 PubMed
- [5] Alexander V Blagov et al.. Pharmaceuticals (Basel). 2023. Potential Use of Antioxidant Compounds for the Treatment of Inflammatory Bowel Disease. doi:10.3390/ph16081150 PubMed
- [6] Amylly Sanuelly da Paz Martins et al.. Oxid Med Cell Longev. 2023. Extraintestinal Manifestations in Induced Colitis: Controversial Effects of N-Acetylcysteine on Colon, Liver, and Kidney. doi:10.1155/2023/8811463 PubMed
- [7] Chris Wallace et al.. Cochrane Database Syst Rev. 2023. Vitamin D for the treatment of inflammatory bowel disease. doi:10.1002/14651858.CD011806.pub2 PubMed
- [8] Cui Liu et al.. J Nanobiotechnology. 2022. Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy. doi:10.1186/s12951-022-01421-w PubMed
- [9] Liping Wang et al.. Int Immunopharmacol. 2022. High-fructose corn syrup promotes proinflammatory Macrophage activation via ROS-mediated NF-κB signaling and exacerbates colitis in mice. doi:10.1016/j.intimp.2022.108814 PubMed
- [10] Shuiliang Ruan et al.. J Biochem Mol Toxicol. 2022. Moronic acid improves intestinal inflammation in mice with chronic colitis by inhibiting intestinal macrophage polarization. doi:10.1002/jbt.23188 PubMed
- [11] Mellany Zepeda et al.. Medwave. 2022. Vitamin D supplementation in inflammatory bowel disease: a narrative review. doi:10.5867/medwave.2022.01.002525 PubMed
- [12] Justyna Kikut et al.. Eur J Nutr. 2021. Diet supporting therapy for inflammatory bowel diseases. doi:10.1007/s00394-021-02489-0 PubMed
- [13] Chengxin Shi et al.. J Inflamm Res. 2021. Selenium-Containing Amino Acids Protect Dextran Sulfate Sodium-Induced Colitis via Ameliorating Oxidative Stress and Intestinal Inflammation. doi:10.2147/JIR.S288412 PubMed
- [14] Emilio J Laserna-Mendieta et al.. J Crohns Colitis. 2018. Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohn's Disease and Ulcerative Colitis. doi:10.1093/ecco-jcc/jjx137 PubMed
- [15] Hanvit Cha et al.. Redox Biol. 2017. Increased susceptibility of IDH2-deficient mice to dextran sodium sulfate-induced colitis. doi:10.1016/j.redox.2017.05.009 PubMed
- [16] Kenichiro Takahashi et al.. Digestion. 2016. Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease. doi:10.1159/000441768 PubMed
- [17] Marco Pelin et al.. Chem Res Toxicol. 2015. Role of oxidative stress mediated by glutathione-s-transferase in thiopurines' toxic effects. doi:10.1021/acs.chemrestox.5b00019 PubMed
- [18] Suleyman Uraz et al.. Scand J Clin Lab Invest. 2013. N-acetylcysteine expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic acid-induced colitis in rats. doi:10.3109/00365513.2012.734859 PubMed
- [19] Eduard Cabré et al.. Br J Nutr. 2012. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. doi:10.1017/S0007114512001626 PubMed
- [20] Eduard Cabré et al.. World J Gastroenterol. 2012. Impact of environmental and dietary factors on the course of inflammatory bowel disease. doi:10.3748/wjg.v18.i29.3814 PubMed
- [21] Thomas Sawidis et al.. Pharm Biol. 2010. Chios mastic, a natural supplement for zinc to enhance male sexuality and prostate function. doi:10.3109/13880200903029399 PubMed
- [22] Yu You et al.. Dig Dis Sci. 2009. Effect of N-acetylcysteine on the murine model of colitis induced by dextran sodium sulfate through up-regulating PON1 activity. doi:10.1007/s10620-008-0563-9 PubMed
- [23] Julien Gommeaux et al.. Mol Cell Biol. 2007. Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. doi:10.1128/MCB.01454-06 PubMed
- [24] Gabriel A Agbor et al.. J Agric Food Chem. 2007. Effect of selenium- and glutathione-enriched yeast supplementation on a combined atherosclerosis and diabetes hamster model. doi:10.1021/jf0711901 PubMed
- [25] Ali Cetinkaya et al.. Tohoku J Exp Med. 2005. Beneficial effects of N-acetylcysteine on acetic acid-induced colitis in rats. doi:10.1620/tjem.206.131 PubMed
- [26] E Akgun et al.. J Int Med Res. 2005. Effects of N-acetylcysteine treatment on oxidative stress in acetic acid-induced experimental colitis in rats. doi:10.1177/147323000503300207 PubMed
- [27] B Salh et al.. J Leukoc Biol. 2002. Dissociated ROS production and ceramide generation in sulfasalazine-induced cell death in Raw 264.7 cells. PubMed
- [28] E Ardite et al.. Lab Invest. 2000. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. doi:10.1038/labinvest.3780077 PubMed
- [29] S Cuzzocrea et al.. Mol Med. 2000. Role of free radicals and poly(ADP-ribose) synthetase in intestinal tight junction permeability. PubMed
- [30] N J Simmonds et al.. Aliment Pharmacol Ther. 1999. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal … doi:10.1046/j.1365-2036.1999.00484.x PubMed
- [31] A D Millar et al.. Gut. 1996. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. doi:10.1136/gut.39.3.407 PubMed
Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.